Public health insurance programs across countries
A wave of GLP-1 weight‑loss drugs is reshaping employer coverage, consumer use, and government pricing. The US launches Medicare coverage for weight‑loss GLP‑1s via the Bridge program with a $50 monthly copay, while the UK approves an oral Wegovy pill and PwC Strategy& projects a surge in UK usage to seven million by 2027. Employers face rising costs; patients may gain broader access.
Struggling rural hospitals in the US face closure risks despite a $50 billion federal fund aimed at reform. The fund, part of recent legislation, is insufficient to cover projected losses and is focused on innovation rather than hospital stabilization, raising concerns about healthcare access in rural communities.
Republicans are tapping Trump turnout power while shaping a cost‑of‑living policy platform, aiming to avoid a pure referendum on the president. Democrats counter with a 10‑bill progressive agenda and restructuring of district maps, signaling a high‑stakes clash ahead of midterms and 2028 considerations.
This report synthesises perspectives on long-term care costs as dementia affects aging populations. It highlights family financial strain, the need for elder-law planning, and the role of Medicare/Medicaid in funding care, with practical guidance on conversations and planning.
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Trust funds for Old-Age and Survivors Insurance and Medicare face earlier depletion than previously forecast. PWBM projects depletion by 2033 for OASI and 2034 for combined funds, while the official trustees warn longer-term pressures. Lawmakers face urgent choices on taxes, benefits, and program integrity as costs rise for aging Americans.
The Justice Department has charged Jason Finkelstein and associates in a yearslong scheme that offered unnecessary heart screening for student-athletes, with kickbacks to school officials and phony diagnoses to obtain insurance reimbursement. One patient died after being misdiagnosed; investigations spotlight a broader push to curb healthcare fraud.